Clinical Trial of Endovenous 940 and 1470 Laser Ablation for Treating Great Saphenous Veins (COLA)
Primary Purpose
Varicose Veins, Insufficiency of Great Saphenous Vein
Status
Completed
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
Endovenous laser ablation (EVLA)
Sponsored by
About this trial
This is an interventional treatment trial for Varicose Veins
Eligibility Criteria
Inclusion Criteria:
- Patients over 18 years old
- Insufficiency of the GSV measured with ultrasound imaging, reflux > 0.5 sec, and diameter of vein > 0.5 cm
- Symptoms of chronic venous insufficiency, including complaints related to varicose veins (≥ C2)
- No prior treatment of the insufficient GSV
- Informed consent
Exclusion Criteria:
- Acute deep or superficial vein thrombosis
- Agenesis of deep vein system
- Vascular malformation or syndrome
- Post-thrombotic syndrome, occlusive type
- Pregnancy
- Immobility
- Allergy to lidocaine
- Arterial insufficiency
- Diameter of GSV ≤ 0.5 mm at puncture site
Sites / Locations
- Erasmus Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
EVLA 940 nm
EVLA 1470 nm
Arm Description
Outcomes
Primary Outcome Measures
Pain score and use of painkillers
A questionnaire including a numeric rating scale (NRS) of pain is filled in by the patient.
Treatment satisfaction
A NRS of satisfaction is filled in by the patient.
Health related quality of life
Dutch Translated Aberdeen Varicose Vein Questionnaire (AVVQ) and EQ-5D questionnaire are filled in by the patient.
Secondary Outcome Measures
Number of participants with adverse events
Minor complications: ecchymoses and hyperpigmentation. Major complications: deep and superficial venous thrombosis (embolic events), nerve injury, skin burns, and (sub)cutaneous infections.
Occlusion of the treated GSV (effectiveness)
Obliteration of varicose vein and/or absence of reflux (>0.5 sec. of retrograde flow) along the treated segment of the GSV. This is measured using US examination.
Full Information
NCT ID
NCT01637181
First Posted
June 18, 2012
Last Updated
February 10, 2015
Sponsor
Erasmus Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT01637181
Brief Title
Clinical Trial of Endovenous 940 and 1470 Laser Ablation for Treating Great Saphenous Veins
Acronym
COLA
Official Title
Comparative Randomized Clinical Trial of Endovenous 940 nm Laser Ablation Versus Endovenous 1470 nm Laser Ablation for Treatment of Great Saphenous Veins
Study Type
Interventional
2. Study Status
Record Verification Date
February 2015
Overall Recruitment Status
Completed
Study Start Date
May 2012 (undefined)
Primary Completion Date
October 2014 (Actual)
Study Completion Date
December 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Erasmus Medical Center
4. Oversight
5. Study Description
Brief Summary
A clinical randomized controlled trial, comparing 2 endovenous laser ablation (EVLA) techniques in patients with insufficiency of the great saphenous vein (GSV). There are multiple EVLA devices available, with different wavelengths. In the Netherlands, 940 nm Diode and 1470 nm Nd:Yag laser are the most frequently used devices. Both devices also proven to be equally effective in occluding the GSV. However, little is known about differences in patient-related outcomes. Therefore, the primary outcomes of this comparative clinical trial of 940 nm and 1470 nm EVLA, are pain scores, patient satisfaction and scores of health related and varicose-specific questionnaires. The secondary outcomes are complications and effectiveness of the treatment. It is thought that possibly the 1470 nm ELVA will give lower pain scores and higher patient satisfaction than 940 nm EVLA. No differences are expected in complication rate and effectiveness between the two treatments.
Detailed Description
* Study type: Interventional. Randomized comparative clinical trial..
Outcome measures:
Primary study outcomes: Patient reported outcomes: 1. Pain score and use of painkillers, assessed with a numeric rating scale (NRS) of pain. 2. Treatment satisfaction, assessed with a NRS of satisfaction. 3. Health related quality of life, assessed with Dutch translated Aberdeen Varicose Vein Questionnaire (AVVQ) and EQ-5D questionnaire.
Secondary study outcomes: 1. Number of patients with adverse events. Major complications: deep and superficial venous thrombosis (embolic events), nerve injury, skin burns, and (sub)cutaneous infections. Minor complications: ecchymosis and hyperpigmentation. 2. Obliteration of varicose vein and/or absence of reflux (> 0.5 sec. of retrograde flow) along the treated segment of the GSV. This is measured using US examination.
Outcome measures time frame:
Follow-up of one year, with outcome measures at baseline, 1 week, 3 months and 1 year post treatment.
* Focus of the study: Varicose great saphenous veins (GSV)
Intervention information:
Intervention name: endovenous laser ablation (EVLA)
Intervention type: 1. EVLA with 940 nm Diode laser 2. EVLA with 1470 nm Nd:Yag laser
Arm information: both interventions are active comparators.
Locations:
Rotterdam, Zuid-Holland, The Netherlands
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Varicose Veins, Insufficiency of Great Saphenous Vein
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
142 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
EVLA 940 nm
Arm Type
Active Comparator
Arm Title
EVLA 1470 nm
Arm Type
Active Comparator
Intervention Type
Procedure
Intervention Name(s)
Endovenous laser ablation (EVLA)
Intervention Description
EVLA with 940 nm Diode laser EVLA with 1470 nm Nd:Yag laser With both devices, obliteration of the varicose vein is obtained by heating the vein, using emission of laser light.
Primary Outcome Measure Information:
Title
Pain score and use of painkillers
Description
A questionnaire including a numeric rating scale (NRS) of pain is filled in by the patient.
Time Frame
1 week post treatment
Title
Treatment satisfaction
Description
A NRS of satisfaction is filled in by the patient.
Time Frame
1 week post treatment
Title
Health related quality of life
Description
Dutch Translated Aberdeen Varicose Vein Questionnaire (AVVQ) and EQ-5D questionnaire are filled in by the patient.
Time Frame
0 and 12 weeks post treatment
Secondary Outcome Measure Information:
Title
Number of participants with adverse events
Description
Minor complications: ecchymoses and hyperpigmentation. Major complications: deep and superficial venous thrombosis (embolic events), nerve injury, skin burns, and (sub)cutaneous infections.
Time Frame
The adverse events will be assessed at 1 and 12 weeks post treatment.
Title
Occlusion of the treated GSV (effectiveness)
Description
Obliteration of varicose vein and/or absence of reflux (>0.5 sec. of retrograde flow) along the treated segment of the GSV. This is measured using US examination.
Time Frame
The rates will be compared between 940 nm and 1470 nm endovenous laser at time 1, 12 and 52 weeks post treatment.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients over 18 years old
Insufficiency of the GSV measured with ultrasound imaging, reflux > 0.5 sec, and diameter of vein > 0.5 cm
Symptoms of chronic venous insufficiency, including complaints related to varicose veins (≥ C2)
No prior treatment of the insufficient GSV
Informed consent
Exclusion Criteria:
Acute deep or superficial vein thrombosis
Agenesis of deep vein system
Vascular malformation or syndrome
Post-thrombotic syndrome, occlusive type
Pregnancy
Immobility
Allergy to lidocaine
Arterial insufficiency
Diameter of GSV ≤ 0.5 mm at puncture site
Facility Information:
Facility Name
Erasmus Medical Center
City
Rotterdam
ZIP/Postal Code
3015 CA
Country
Netherlands
12. IPD Sharing Statement
Citations:
PubMed Identifier
26661521
Citation
Malskat WS, Giang J, De Maeseneer MG, Nijsten TE, van den Bos RR. Randomized clinical trial of 940- versus 1470-nm endovenous laser ablation for great saphenous vein incompetence. Br J Surg. 2016 Feb;103(3):192-8. doi: 10.1002/bjs.10035. Epub 2015 Dec 14.
Results Reference
derived
Learn more about this trial
Clinical Trial of Endovenous 940 and 1470 Laser Ablation for Treating Great Saphenous Veins
We'll reach out to this number within 24 hrs